General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Media releases

February 24, 2014 07:15 CET

Novartis provides second US university with Bexsero® to help protect students and staff against potentially deadly meningitis B disease

  • FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada
  • Novartis is pursuing a US license that would allow immediate public health response to outbreaks and make Bexsero available to American families
  • MenB is an unpredictable disease, easily misdiagnosed, can kill within 24 hours and leaves those affected with serious lifelong disabilities

Basel, February 24, 2014 - Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7. In the last three months, the Food and Drug Administration (FDA) has approved the use of Bexsero twice in response to MenB outbreaks at US college campuses[1]. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB[2].

Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug (IND) designation. Under this process, many weeks are required to gain administrative approvals, organize supply and delivery of the vaccine from countries where it is being used, and decide how vaccination programs will be managed at local sites.

Granting a US license for Bexsero for use in all adolescents and young adults would enable immediate response to future outbreaks and allow US families to have access to a vaccine to help protect against MenB.

"Having lost my son to meningitis, I know how dangerous the disease is and how quickly it can strike someone," said Lynn Bozof, President of the National Meningitis Association. "Because it is impossible to know who will be affected and when, we look forward to the day when there is a licensed MenB vaccine in the US, which could help prevent other families from experiencing the devastation this disease causes."

"These recent outbreaks remind us how unpredictable the disease can be and demonstrate the need to license Bexsero in the US. This would enable us to quickly respond to future outbreaks, while also having a vaccine available for those who might pre-emptively choose to protect themselves against the disease," said Andrin Oswald, Division Head, Novartis Vaccines. "We will continue to work with the FDA to pursue a potential license for Bexsero in the US to help fulfill this public health need."

Novartis has submitted data from Bexsero's comprehensive clinical program to the FDA, including information from clinical studies with almost 8,000 infant, children, adolescent and adult participants, which supported the licensure of the vaccine in Europe, Australia and Canada[1].

While rare, MenB is a bacterial infection that progresses rapidly and can lead to death or permanent disability within 24 hours of symptom onset[3],[4]. Because initial symptoms are often unspecific and flu-like, it can be difficult for even a healthcare professional to diagnose the disease in its early stages. About one in 10 of those with the disease will die despite treatment; and of those who do survive, one in five will suffer from devastating, life-long disabilities such as brain damage, hearing loss or limb loss[2].

Adolescents and young adults are at an increased risk of contracting meningococcal disease, which is associated with changes in behavior and lifestyle[5],[6],[7]. These age groups also have an unusually high case fatality rate from meningococcal disease[5],[6]. Further, adolescents and young adults are more likely to be carriers of the bacteria than other age groups and can transmit the bacteria to family and friends[8].

Outbreaks of invasive meningococcal disease happen without warning and the most effective way to prevent and control this aggressive disease is through the use of vaccines. A study published in Clinical Infectious Diseases in 2006 characterized outbreak-associated and sporadic cases in the US from 1992 through 2002 and identified 69 outbreaks (3-14 outbreaks per year)[9]. From a public health standpoint, these outbreaks are disruptive to individuals and their communities, as they can create alarm and require extensive resources to manage, and those affected by the disease can suffer from serious disabilities. Currently, adolescents in the US are recommended to be vaccinated against four other serogroups that can cause bacterial meningitis (A, C, W-135 and Y)[10].

For the vaccination program at UCSB, the Centers for Disease Control and Prevention (CDC) recommends that the following groups receive the vaccine:

  • All UCSB undergraduates and University Immersion Program students
  • The small number of faculty, staff and graduate students who have certain specific medical conditions or who live in University-owned dormitory-style residence halls[11]

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "potentially," "pursuing," "would," "unpredictable," "can," "will," "offered," "could," "might," "pre-emptively," "continue," "pursue," "potential," "risk," "more likely," "recommends," or similar terms, or by express or implied discussions regarding potential additional marketing approvals for Bexsero, or regarding potential future revenues from Bexsero. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Bexsero will be submitted or approved for sale in the US or additional markets, or at any particular time. Nor can there be any guaranty that Bexsero will be commercially successful in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References
[1] Centers for Disease Control and Prevention. Serogroup B Meningococcal Vaccine and Outbreaks: Questions and Answers. Available at: http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupB.html. Accessed February 2014.
[2] Centers for Disease Control and Prevention. Princeton University Meningococcal Disease Outbreak. December 2013. Available at: http://www.cdc.gov/meningococcal/outbreaks/princeton.htm. Accessed February 2014.
[3] Mayo Foundation for Medical Education and Research. Meningitis. April 2011. Available at: http://www.mayoclinic.com/health/meningitis/DS00118/DSECTION=symptoms. Accessed February 2014.
[4] World Health Organization. Meningococcal meningitis. Fact sheet #141. November 2012. Available at: http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed February 2014.
[5] Cohn, A. et al. Changes in Neisseria meningitides Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease. Clinical Infectious Diseases. (2013) 50 (2): 184-191. Available at http://cid.oxfordjournals.org/content/50/2/184.full.pdf+html. Accessed February 2014.
[6] Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive Meningococcal Disease in Adolescents and Young Adults. JAMA. 2001:286(6): 694-699. Available at: http://jama.jamanetwork.com/article.aspx?articleid=194084. Accessed February 2014.
[7] Harrison LH. A New Era in Adolescent Immunization. National Foundation of Infectious Diseases. Available at: http://www.medscape.com/infosite/nfid/article-1. Accessed February 2014.
[8] National Advisory Committee on Immunization. Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations. Canada Communicable Disease Report. April 2009, Vol. 36. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf. Accessed February 2014.
[9] Brooks R, Woods CW, Benjamin DK, Jr., Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clinical Infectious Disease. (2006) 43 (1): 49-54. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16758417. Accessed February 2014.
[10] Centers for Disease Control and Prevention. University of California, Santa Barbara Meningococcal Disease Outbreak. January 2013. Available at: http://www.cdc.gov/meningococcal/outbreaks/ucsb.html. Accessed February 2014.
[11] Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). March 2013. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm. Accessed February 2014.


# # #



Novartis Media Relations

Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
Liz Power
Novartis Vaccines
+1 617 871 7985 (direct)
+1 617 583 3015 (mobile)
elizabeth.power@novartis.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.

Novartis Investor Relations

Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Susan Donofrio +1 862 778 9257
e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com

 

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.